Aveta Biomics

Aveta Biomics, based in Bedford, the United States, is a biotechnology company. Aveta Biomics develops oral immunotherapies for cancer that apply principles of evolutionary biology to reprogram the tumour-immune ecosystem upstream of checkpoint pathways. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma. The largest, NCT06011109 (Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.